Singapore’s Aslan Pharma lines up an $86M IPO to fund pivotal cancer drug studies

Carl Firth

With its lead oncology drug in a pivotal study for biliary tract cancer and a slate of key catalysts coming up in other trials, Singapore-based Aslan Pharmaceuticals has filed for an IPO on Nasdaq, with plans to raise around $86 million. Helmed by Carl Firth — the former BD chief for AstraZeneca in Asia who owns 4.7% of the stock — Aslan is a small biotech with a global strategy to roll out its cancer drugs in China, the US and Europe. The lead is varlitinib, a pan-HER drug that is also in the clinic for gastric, breast and colorectal cancers. The company plans to trade under the $ASLN symbol, taking advantage of the current hot market for biotechs.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->